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Abstract To investigate acquired resistance to oxaliplatin, we
selected two resistant clones from the HCT116 cell line. We
found that the resistant phenotype was associated with resis-
tance to oxaliplatin-induced apoptosis as demonstrated by
FACS analysis and by Western blotting of caspase 3 activation.
In addition, the resistant phenotype showed a concomitant re-
sistance to lonidamine and arsenic trioxide which are inducers of
mitochondrial apoptosis. Furthermore, a complete loss of Bax
expression due to a frameshift mutation was observed in the
most resistant clone. Taken together, these ¢ndings suggest
that altered mitochondrial-mediated apoptosis could play a
role in oxaliplatin resistance.
) 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Colorectal cancer is the second leading cause of cancer-re-
lated deaths in Western countries [1,2]. The number of new
cases of colorectal cancer worldwide is increasing, and ap-
proximately one half of colorectal cancer patients develop
metastatic disease. The prognosis for these patients is poor
because of frequent chemoresistance which is either intrinsic
or acquired during treatment.
For a long time, 5-£uorouracil (5-FU) was the only drug
used in advanced colorectal cancer until two novel chemother-
apeutic agents, oxaliplatin and irinotecan in conjunction with
5-FU, were introduced and shown to have a clinical bene¢t
[3,4]. In particular, oxaliplatin is a third generation platinum
complex with a wide spectrum of anticancer activity. Oxali-
platin in association with 5-FU is active in patients with
5-FU-resistant disease (response rates up to 30^40% after
5-FU treatment failure) [5].
Resistance to conventional platinum derivatives such as cis-
platin has been extensively studied and was shown to result
from several mechanisms, including decreased drug transport,
increased cytoplasmic detoxi¢cation by glutathione or metal-
lothioneins, enhanced DNA repair and defect in apoptosis [6].
Although oxaliplatin produces the same type of DNA cross-
links as cisplatin [7], di¡erences still exist between the two
agents as shown by the fact that cisplatin-resistant cells gen-
erally remain sensitive to oxaliplatin. DNA repair-related re-
sistance to cisplatin can be due to an increase in nucleotide
excision repair or to a defect in DNA mismatch repair
(MMR), resulting from replicative by-pass of platinum ad-
ducts [8,9]. The same defects in MMR or replicative by-
pass, however, do not confer resistance to oxaliplatin [10,11].
Only two studies have reported the identi¢cation of a po-
tential molecular mechanism for resistance to oxaliplatin. The
¢rst described the increase of Q-glutamyl transpeptidase activ-
ity leading to elevation in cellular GSH in sublines derived
from A2780 ovarian carcinoma cell line [12]. Based on the
same cellular model, a second study demonstrated reduced
platinum accumulation and DNA^platinum adduct levels as-
sociated with oxaliplatin resistance [13]. The paucity of infor-
mation relative to oxaliplatin resistance underlines the fact
that a better understanding of the molecular events governing
oxaliplatin activity and resistance is critical for its rational
use.
To improve the knowledge of the molecular basis of resis-
tance to oxaliplatin, we generated an in vitro cellular model of
resistance derived from the HCT116 colon carcinoma cell line.
The acquired resistance to oxaliplatin was found to be asso-
ciated with resistance to oxaliplatin-induced apoptosis and
with a concomitant resistance to lonidamine-induced apopto-
sis, suggesting a defect in the mitochondrial apoptotic path-
way. Additionally, a loss of Bax expression was found in the
most resistant clone (HCT116/R2), supporting the idea that
Bax could represent one of the altered factors contributing to
an apoptotic defect in oxaliplatin-resistant cells.
2. Materials and methods
2.1. Cell culture
Three clones (HCT116/S, HCT116/R1 and HCT116/R2) were de-
rived from the HCT116 cell line (ATCC, Manassas, VA, USA) and
were grown in RPMI 1640 medium supplemented with 10% fetal
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bovine serum and 2 mM glutamine without antibiotics. HCT116/R1
and HCT116/R2 cell lines were selected by exposure to stepwise in-
creased concentrations of oxaliplatin and were maintained in the pres-
ence of 5 WM and 10 WM oxaliplatin, respectively. Before each experi-
ment, HCT116/R1 and HCT116/R2 cells were cultured without
oxaliplatin for 1 week.
2.2. Drug sensitivity assay
Growth inhibition assays were performed by seeding 4000 cells per
well in 96-well microtiter plates. After incubation for 24 h for cell
attachment, the drugs were added and the cells were incubated again
for 48 h. Each drug concentration was tested in triplicate. Cytotox-
icity was measured by the WST-1 colorimetric assay (Boehringer
Mannheim, Germany) according to the manufacturer’s recommenda-
tions. Absorbance was measured at 450 nm 3 h after addition of the
WST-1 substrate. The results were expressed in terms of the concen-
tration of drug required to inhibit cell growth by 50% relative to
untreated cells (IC50).
2.3. Detection of apoptotic cells by £ow cytometry
The cells were treated with 15 WM oxaliplatin or 35 WM irinotecan
for 48 h and with 220 WM lonidamine or 40 WM arsenic trioxide for
24 h. For oxaliplatin, irinotecan and lonidamine treatments, the cells
were washed and labeled using the £uorescein isothiocyanate (FITC)-
labeled annexin V method (FITC-annexin V, Boehringer Mann-
heim)[14] according to the manufacturer’s recommendations. For ar-
senic trioxide treatment, the cells were washed and incubated with the
MitoCapture reagent (BioVision, Mountain View, CA, USA) accord-
ing to the manufacturer’s recommendations. After labeling, apoptotic
cells were analyzed with a FACScan £uorescence-activated cell sorter
(Becton Dickinson, Franklin Lakes, MD, USA) using the FITC chan-
nel.
2.4. Western blotting analysis
Subcon£uent monolayers of cells were washed twice in phosphate-
bu¡ered saline (PBS; pH 7.4, 135 mM NaCl, 2.68 mM KCl, 1.47 mM
KH2PO4, 6.38 mM Na2HPO4) and lysed in SDS bu¡er (bromophenol
blue, 0.7 M 2-mercaptoethanol, 2% SDS, 10% glycerol and 0.5 M
Tris^HCl). The extracts were sonicated and then boiled for 5 min.
100 000 cells per lane were separated by 12% SDS^PAGE and trans-
ferred to a polyvinylidene di£uoride membrane by electroblotting.
Blots were blocked 50 min at room temperature in PBS^0.1% Tween
20 containing 5% non-fat dried milk, incubated for 2 h at room
temperature with primary antibody [anti-Bax mouse monoclonal anti-
body (Neomarkers, Fremont, CA, USA), anti-Bak mouse monoclonal
antibody (Oncogene, Boston, MA, USA), anti-Bcl2 mouse monoclo-
nal antibody (Neomarkers), anti-Bcl-XL mouse monoclonal (Phar-
Mingen, San Diego, CA, USA), anti-procaspase 3 mouse monoclonal
antibody (BD Biosciences, Palo Alto, CA, USA) or rabbit anti-cas-
pase 3 antibody (Cell Signaling, Beverly, MA, USA)] and then washed
with PBS^0.1% Tween 20. Blots were then incubated for 1 h at room
temperature in blocking bu¡er with the corresponding peroxidase-
conjugated secondary anti-mouse or anti-rabbit IgG antibody (Sigma,
St. Louis, MO, USA) and washed again. Bound complexes were de-
tected using the ECL-Plus reagent (Amersham Biosciences, France)
according to the manufacturer’s recommendations. To con¢rm equiv-
alent loading and transfer of proteins, anti-K-tubulin antibody (Sig-
ma) was used.
2.5. Ampli¢cation of the Bax G8 tract region for sequencing
Genomic DNA from each variant derived from the HCT116 cell
line (HCT116/S, HCT116/R1 and HCT116/R2) was isolated. A 94-bp
region encompassing the Bax G8 tract spanning codons 38^41 was
ampli¢ed by PCR using the 5P-ATC CAG GAT CGA GCA GGG
CG-3P and 5P-ACT CGC TCA GCT TCT TGG TG-3P primers as
described by Ionov et al.[15]. PCR was carried out with Taq poly-
merase (MBI Fermentas, Vilnius, Lithuania) for one cycle at 94‡C
followed by 30 cycles at 94‡C for 30 s, 55‡C for 30 s and 72‡C for
30 s. PCR products were puri¢ed using the GFX PCR DNA and gel
band puri¢cation kit (Amersham Biosciences, France) before sequenc-
ing.
3. Results
3.1. Establishment of a cellular model for oxaliplatin resistance
To compare sensitive and resistant phenotypes in the con-
text of the same genetic background, we derived several sub-
lines from the human colorectal cell line HCT116. This cell
line was previously found to be sensitive to oxaliplatin in the
National Cancer Institute’s Anticancer Drug screening panel
[16]. The homogeneity of the HCT116 cells was veri¢ed by
isolating di¡erent clones and determining their sensitivity to
oxaliplatin: the IC50 values for these clones ranged from 0.3
to 1 WM (data not shown). One clone, referred to as HCT116/
S, was selected for the present study and used as the sensitive
variant. In parallel, after the HCT116 cell line had been con-
tinuously grown in the presence of stepwise increasing con-
centrations of oxaliplatin (from 0.1 WM to 10 WM), two resis-
tant clones (HCT116/R1 and HCT116/R2) were isolated.
HCT116/R1 and HCT116/R2 are 28- and 68-fold more resis-
tant than HCT116/S, respectively (Table 1).
To evaluate the speci¢city of the resistance to oxaliplatin,
we tested the sensitivity of the two oxaliplatin-resistant clones
to cisplatin and irinotecan. Cisplatin was selected because it is
related to oxaliplatin. Oxaliplatin and cisplatin generate sim-
ilar inter- and intra-strand DNA cross-links. However, the
DNA^platinum adducts produced by oxaliplatin are less ac-
cessible to DNA repair mechanisms, probably due to the pres-
ence of its bulky diaminocyclohexane group. Cisplatin did not
demonstrate e⁄cacy in the treatment of colorectal cancers.
The cross-resistance to irinotecan was also assessed because
this drug, an e⁄cient inhibitor of DNA topoisomerase I, was
recently introduced for the treatment of colorectal cancers.
Results presented in Table 1 show that a low cross-resistance
to irinotecan was observed in HCT116/R1. Cross-resistance in
this model was not correlated, however, with the oxaliplatin
resistance level since there was no cross-resistance to irinote-
can in HCT116/R2. For cisplatin, we observed minimal cross-
resistance in both HCT116/R1 and HCT116/R2 (2.1- and 2.9-
fold, respectively). This low level of cross-resistance to cisplat-
in con¢rmed the speci¢city of the resistance to oxaliplatin in
our model.
Table 1
Sensitivity of the oxaliplatin-resistant cell lines to cisplatin and irinotecan
HCT116 clone IC50 (WM)a
Oxaliplatin Cisplatin Irinotecan
HCT116/S 0.32S 0.08 (1.0)b 4.7S 1.8 (1.0) 7.7 S 3.8 (1.0)
HCT116/R1 8.9S 3.6 (27.8) 9.7S 2 (2.1) 32.3S 5.1 (4.2)
HCT116/R2 21.9S 6.3 (68.4) 13.4S 6.6 (2.9) 9.5 S 4.2 (1.2)
aIC50 values were measured by the WST-1 colorimetric assay after continuous exposure to drug for 48 h. Values are meansSS.D. of data ob-
tained from at least three independent experiments.
bNumbers in parentheses are the relative resistance determined as the ratio of the IC50 for the clone divided by the IC50 for the sensitive
HCT116/S cells.
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3.2. Oxaliplatin-resistant phenotypes are associated with a
speci¢c resistance to oxaliplatin-induced apoptosis
As the mechanisms controlling oxaliplatin resistance are
still unknown, we performed a preliminary experiment using
macroarray technology (Atlas Human Cancer 1.2 macroarray,
Clontech, Palo Alto, CA, USA) to gain access to a rapid
overview of genes di¡erentially expressed in the resistant phe-
notype. Comparing the gene expression between the most re-
sistant clone HCT116/R2 and the sensitive clone HCT116/S,
this macroarray analysis showed alterations in the apoptotic
pathway. In particular, the most dramatic change was a
marked down-regulation of the Bax gene in resistant
HCT116/R2 cells (data not shown). On the basis of the results
of this preliminary exploration, we decided to focus our at-
tention on the apoptotic pathway to examine whether oxali-
platin resistance could be associated with dysregulation of
apoptosis.
To this end, we evaluated by FACS analysis the ability of
the three clones HCT116/S, HCT116/R1 and HCT116/R2 to
undergo apoptosis in response to oxaliplatin treatment. To
observe pharmacologically relevant e¡ects, we tested oxalipla-
tin at a concentration of 15 WM, which corresponds approx-
imately to the plasma peak in patients and leads in vitro to
full activation of apoptosis in sensitive cells. As shown in
Fig. 1, oxaliplatin induced apoptosis in the sensitive
HCT116/S cells, but it failed to induce apoptosis in the resis-
tant HCT116/R1 and HCT116/R2 clones. Similar results were
observed at 48, 72 and 96 h after the beginning of oxaliplatin
treatment (data not shown at 72 and 96 h).
We questioned whether or not resistance to apoptosis was
speci¢c for oxaliplatin. For this purpose, cells were treated
with 35 WM irinotecan, which is the concentration we found
to be equitoxic to 15 WM oxaliplatin in HCT116/S cells. Fig. 1
shows that the resistant cells were able to undergo apoptosis
when treated with irinotecan but to a lesser extent than the
HCT116/S cells. The di¡erential sensitivity to irinotecan-in-
duced apoptosis in HCT116/R1 and HCT116/R2 cells ob-
served in Fig. 1 is consistent with the low cross-resistance
between oxaliplatin and irinotecan of the HCT116/R1 cells
(Table 1). These data show that the resistant phenotypes are
speci¢cally associated with a decrease in oxaliplatin-induced
apoptosis. The question remains as to whether this resistance
results from a lower level of injury in the resistant cells or
whether it is due to an alteration of apoptosis. To address this
question, we tested the cellular sensitivity to the apoptosis
inducers lonidamine and arsenic trioxide, known to act di-
rectly on the mitochondrial pathway of apoptosis by opening
the permeability transition pore [17,18].
3.3. Concomitant resistance to lonidamine- and arsenic
trioxide-induced apoptosis in oxaliplatin-resistant
phenotypes
To investigate a possible defect in the mitochondrial apo-
ptotic pathway, we examined the ability of lonidamine and
arsenic trioxide to induce apoptosis in the resistant cells
(HCT116/R1 and HCT116/R2). The percentage of apoptotic
cells was evaluated after treatment with 220 WM lonidamine
or 40 WM arsenic trioxide for 24 h (optimal conditions for
inducing apoptosis in the sensitive clone). Fig. 2A shows
that lonidamine induced marked apoptosis in the sensitive
cells HCT116/S, whereas it only induced limited apoptosis in
HCT116/R1 and no detectable apoptosis in HCT116/R2 cells.
Similarly, Fig. 2B shows that arsenic trioxide induced marked
apoptosis in the sensitive cells, whereas it only induced limited
apoptosis in HCT116/R1 and slightly detectable apoptosis in
HCT116/R2. This last experiment, by directly measuring the
depolarization of the mitochondrial membrane, demonstrated
that there is indeed a functional alteration in the mitochon-
drial apoptotic pathway not only in the R2 clone but also in
the R1 resistant cell line. The correlation between resistance to
oxaliplatin-induced apoptosis and resistance to lonidamine- or
Fig. 1. Evaluation of oxaliplatin- or irinotecan-induced apoptosis in
HCT116-derived sensitive and resistant clones. Apoptosis was eval-
uated 48 h after the beginning of treatment. The percentage of cells
entering apoptosis was determined by FACS analysis using FITC-la-
beled annexin V. Results are the means of three independent experi-
ments; bars, S.D. Cells were treated for 48 h with 15 WM oxalipla-
tin or 35 WM irinotecan.
Fig. 2. Susceptibility to lonidamine- or arsenic trioxide-induced apo-
ptosis in resistant clones. Cells were treated for 24 h with 220 WM
lonidamine (A) or 40 WM arsenic trioxide (As2O3) (B). The percent-
age of cells entering apoptosis was determined by FACS analysis us-
ing FITC-labeled annexin V (A) or the MitoCapture apoptosis de-
tection kit (BioVision), which detects the changes in the
mitochondrial transmembrane potential (B). Results are the means
of three independent experiments; bars, S.D.
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arsenic trioxide-induced apoptosis in the resistant cells
strongly argues in favor of a defect in the mitochondrial ap-
optotic pathway which could contribute to resistance to ox-
aliplatin.
3.4. Molecular analysis of caspase 3, Bax, Bak, Bcl-2 and
Bcl-XL
To further assess the contribution of a defect in the mito-
chondrial apoptotic pathway to the resistance to oxaliplatin,
we studied ¢ve key apoptotic e¡ectors, namely, caspase 3,
Bax, Bak, Bcl-2 and Bcl-XL [19,20].
In the absence of treatment, caspase 3 processing was not
detectable in either of the HCT116 variants (data not shown).
Patterns of caspase 3 activation in the HCT116 variants fol-
lowing oxaliplatin treatment are shown in Fig. 3. Following
treatment with 50 WM oxaliplatin, activated caspase 3 was
detected as two fragments (approximately Mr 19 000 and Mr
17 000) in sensitive HCT116/S cells. In contrast, caspase 3
activation was undetectable in the two resistant clones
HCT116/R1 and HCT116/R2. This di¡erence is not due to
a defect in caspase 3 expression since the procaspase expres-
sion levels were found to be identical in the three cell lines
(Fig. 3). These results demonstrate an association between
resistant phenotypes and loss of caspase 3 activation, which
is consistent with the resistance to oxaliplatin-induced apopto-
sis demonstrated by FACS analysis.
We also investigated Bax expression, given the speci¢city of
Bax for induction of the mitochondrial apoptotic pathway.
Fig. 4A shows that Bax expression was detectable and mark-
edly induced following oxaliplatin treatment in HCT116/S
and HCT116/R1 cells. In the HCT116/R1 variant, resistance
thus did not seem to be due to a modulation of Bax expres-
sion. In contrast, in the most resistant HCT116/R2 clone, Bax
was undetectable independently of oxaliplatin treatment. Loss
of Bax expression con¢rmed and extended the mitochondrial
apoptosis defect associated with oxaliplatin resistance in
HCT116/R2 cells. As a high Bcl-2/Bax ratio is known to favor
cell survival, whereas a low ratio promotes apoptosis, we in-
vestigated Bcl-2 expression (Fig. 4A). Unlike Bax, Bcl-2 ex-
pression remained unchanged in sensitive, resistant and cells
both in the absence and in the presence of oxaliplatin. We also
investigated expression of the pro-apoptotic Bak and the anti-
apoptotic Bcl-XL in order to further characterize the mito-
chondrial apoptotic response (Fig. 4B). In the absence of ox-
aliplatin treatment, Bak and Bcl-XL expression was similar in
the three cell lines. The two proteins were induced by oxali-
platin treatment but at the same level in the three cell lines.
These ¢ndings suggest that the modulation of Bak, Bcl-2 or
Bcl-XL expression is not involved in the acquisition of oxali-
platin resistance in our model.
3.5. Sequencing of the Bax gene
Loss of Bax expression was observed in the most resistant
phenotype. An inherent instability in a G8 tract of the Bax
gene has been demonstrated to be a mutational target in the
case of MMR-de¢cient colorectal cancers [15]. Moreover, mu-
tations in this G8 tract of the Bax gene are particularly fre-
quent in the HCT116 cell line. In addition, such a mutation
was recently suggested to play a key role in the acquisition of
a profound resistance to non- steroid anti-in£ammatory drugs
that could help prevent colon polyps from becoming cancer-
ous [21]. To determine whether the loss of Bax expression in
HCT116/R2 cells was related to a frameshift mutation in the
Bax G8 tract spanning codons 38^41, we sequenced this re-
gion of the Bax gene in all the HCT116 variants. Sequence
analysis revealed that both Bax alleles were mutated in the
HCT116/R2 clone resulting in a deletion of a G base in the
G8 tract (G7/G7 homozygous), whereas the HCT116/S and
HCT116/R1 clones were heterozygous and conserved one
wild-type Bax allele (G8/G7).
4. Discussion
Molecular mechanisms involved in oxaliplatin resistance re-
main to be characterized. In this study we established a cel-
Fig. 3. Western blotting of activated caspase 3 in HCT116 variants
after oxaliplatin treatment. Cells were treated with 50 WM oxalipla-
tin for 24 h before lysate preparation for immunoblot analysis as
described in Section 2. Expression of tubulin was used to control
equivalent protein loading and transfer.
Fig. 4. Western blotting of Bax, Bak, Bcl-2 and Bcl-XL in HCT116 variants prior to or following oxaliplatin treatment. Cells were untreated or
treated with 15 WM oxaliplatin for 48 h or with 50 WM oxaliplatin for 24 h before lysate preparation. Immunoblot analyses were performed as
described in Section 2. Expression of tubulin was used to control equivalent protein loading and transfer
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lular model based on the oxaliplatin-sensitive human colon
carcinoma HCT116 cell line. By growing the cells in increas-
ing concentrations of oxaliplatin, we were able to isolate cell
lines 30- and 70-fold more resistant than the sensitive clone
HCT116/S. The speci¢city of this cellular model for oxalipla-
tin was demonstrated by limited cross-resistance to two com-
monly used anticancer drugs.
By FACS analysis we demonstrated that susceptibility to
apoptosis induced by oxaliplatin was speci¢cally decreased
in resistant cells. Alteration in the activation of caspase 3
following oxaliplatin treatment con¢rmed the reduced apopto-
sis in the resistant cells. The observed concomitant resistance
to lonidamine-induced apoptosis suggests a defect within the
mitochondrial apoptotic pathway in the resistant cells. These
data are strongly supported by the cross-resistance to apopto-
sis induced by arsenic trioxide, another agent able to induce
apoptosis via the mitochondria [18].
Loss of Bax expression was observed only in the most re-
sistant phenotype suggesting that Bax probably represents
only one of the putative mitochondrial altered factors, since
it does not seem to be involved in the resistance of the
HCT116/R1 cells. Nevertheless, these cells exhibited partial
cross-resistance to lonidamine- and arsenic trioxide-induced
apoptosis, suggesting an alteration in the mitochondrial apo-
ptotic pathway.
To date, the molecular mechanisms underlying resistance to
oxaliplatin have only been studied in a cellular model derived
from the A2780 ovarian carcinoma cell line. Two mechanisms
have been associated with oxaliplatin resistance in this cellular
model: an increase in the Q-glutamyl transpeptidase activity
leading to elevation in cellular GSH [12] and a reduction in
platinum accumulation and DNA^platinum adduct levels [13].
Nevertheless, the contribution of apoptosis to the resistance to
oxaliplatin has never been described before and represents an
interesting new pathway to investigate further. Indeed, anti-
cancer drugs have typically been thought to induce apoptosis
by a¡ecting intrinsic death pathways that converge to the
release of apoptogenic molecules from the mitochondria into
the cytosol [22,23]. The ability of cells to maintain a balance
in favor of apoptotic cell death appears to be an important
determinant of e⁄cacy in many anticancer chemotherapies,
and alterations in apoptotic pathways may often be associated
with treatment failure. Strategies to overcome drug resistance
by modulating apoptosis are now under investigation with
several clinical trials in progress [24].
In conclusion, our study shows that acquisition of resis-
tance to oxaliplatin was associated with alterations within
the mitochondrial apoptotic pathway in our cellular model.
This report underlines the fact that perturbations within the
mitochondrial apoptotic pathway may contribute to oxalipla-
tin resistance and that Bax could contribute to this apoptotic
defect in some cases. Further studies are needed to clarify the
involvement of mitochondrial apoptosis in oxaliplatin resis-
tance in this and other colorectal cancer cell models.
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